Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inno8 in Haemophilia A
NCT07220564Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Nanobodies (VHH)
- Countries
- 12
01
Overview
Phase 1 trial of Inno 8 in hemophilia A (3 cohorts), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Oct 2025; status: recruiting.
02
Drugs
Inno 8
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT07220564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220564.